See more : Hansa Biopharma AB (publ) (HNSBF) Income Statement Analysis – Financial Results
Complete financial analysis of Helix BioPharma Corp. (HBPCF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Helix BioPharma Corp., a leading company in the Biotechnology industry within the Healthcare sector.
- Federal National Mortgage Association (FNMA) Income Statement Analysis – Financial Results
- Shanghai Yaoji Technology Co., Ltd. (002605.SZ) Income Statement Analysis – Financial Results
- Diamondhead Casino Corporation (DHCC) Income Statement Analysis – Financial Results
- Global Link Communications Holdings Limited (8060.HK) Income Statement Analysis – Financial Results
- Dongguang Chemical Limited (1702.HK) Income Statement Analysis – Financial Results
Helix BioPharma Corp. (HBPCF)
About Helix BioPharma Corp.
Helix BioPharma Corp. operates as an immune-oncology company in Canada. The company is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. It has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. The company is headquartered in Toronto, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.26M | 4.53M | 4.43M | 3.84M | 3.59M | 3.42M |
| Cost of Revenue | 13.00K | 12.00K | 173.00K | 212.00K | 56.00K | 167.00K | 130.00K | 134.00K | 0.00 | 0.00 | 0.00 | 1.74M | 1.64M | 1.67M | 1.52M | 1.24M | 1.14M |
| Gross Profit | -13.00K | -12.00K | -173.00K | -212.00K | -56.00K | -167.00K | -130.00K | -134.00K | 0.00 | 0.00 | 0.00 | 2.52M | 2.89M | 2.77M | 2.33M | 2.35M | 2.29M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 59.13% | 63.77% | 62.36% | 60.53% | 65.50% | 66.73% |
| Research & Development | 5.28M | 4.54M | 5.88M | 5.87M | 5.01M | 6.08M | 7.06M | 5.82M | 4.89M | 5.24M | 5.03M | 7.45M | 7.32M | 10.72M | 10.32M | 5.06M | 4.12M |
| General & Administrative | 299.00K | 595.00K | 3.25M | 2.72M | 2.47M | 2.44M | 3.21M | 3.84M | 3.89M | 3.50M | 3.20M | 4.58M | 6.52M | 4.45M | 4.94M | 4.80M | 4.47M |
| Selling & Marketing | 746.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.09M | 1.12M | 1.13M | 969.00K | 0.00 | 0.00 |
| SG&A | 1.05M | 595.00K | 3.25M | 2.72M | 2.47M | 2.44M | 3.21M | 3.84M | 3.89M | 3.50M | 3.20M | 5.67M | 7.64M | 5.58M | 5.91M | 4.80M | 4.47M |
| Other Expenses | -59.00K | -501.00K | -142.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 6.33M | 6.04M | 9.13M | 8.62M | 7.49M | 8.55M | 10.26M | 9.66M | 8.78M | 8.74M | 8.23M | 13.12M | 15.37M | 16.67M | 16.62M | 10.14M | 10.36M |
| Cost & Expenses | 6.33M | 6.04M | 9.13M | 8.62M | 7.49M | 8.55M | 10.26M | 9.66M | 8.78M | 8.74M | 8.23M | 14.86M | 17.01M | 18.34M | 18.13M | 11.37M | 11.50M |
| Interest Income | 47.00K | 4.00K | 0.00 | 25.00K | 3.00K | 9.00K | 16.00K | 26.00K | 56.00K | 43.00K | 50.00K | 125.00K | 188.00K | 49.00K | 339.00K | 645.00K | 496.00K |
| Interest Expense | 14.00K | 18.00K | 15.00K | 25.00K | 1.00K | 29.00K | 14.00K | 17.00K | 13.00K | 19.00K | 25.00K | 17.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 13.00K | 12.00K | 199.00K | 211.00K | 125.00K | 165.00K | 130.00K | 134.00K | 133.00K | 232.00K | 396.00K | 699.00K | 404.00K | 429.00K | 286.00K | 270.00K | 446.00K |
| EBITDA | -6.31M | -6.53M | -9.07M | -8.38M | -6.72M | -8.38M | -10.12M | -9.52M | -8.64M | -8.46M | -7.78M | -9.78M | -10.61M | -13.53M | -13.91M | -7.51M | -6.31M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -229.46% | -294.53% | -291.27% | -358.58% | -218.32% | -184.14% |
| Operating Income | -6.33M | -6.54M | -9.61M | -8.59M | -7.49M | -8.54M | -10.25M | -9.63M | -8.72M | -8.69M | -8.18M | -17.46M | -12.48M | -13.34M | -14.06M | -8.11M | -6.75M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -409.74% | -275.31% | -300.95% | -366.02% | -225.84% | -197.17% |
| Total Other Income/Expenses | 36.00K | -523.00K | -443.00K | 55.00K | -32.00K | -79.00K | 35.00K | -8.00K | -3.00K | 53.00K | 16.00K | 32.00K | 1.46M | -468.00K | -25.00K | 972.00K | 505.00K |
| Income Before Tax | -6.29M | -6.56M | -9.57M | -8.56M | -7.53M | -8.63M | -10.06M | -9.67M | -8.78M | -8.68M | -8.19M | -17.42M | -11.01M | -14.42M | -14.08M | -6.81M | -7.57M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -408.99% | -243.03% | -325.28% | -366.68% | -189.67% | -221.06% |
| Income Tax Expense | 0.00 | -484.00K | -1.66M | 449.00K | 1.00K | 29.00K | 14.00K | 17.00K | -37.00K | 19.00K | -6.62M | 17.00K | 334.00K | 46.00K | 18.00K | 153.00K | 105.00K |
| Net Income | -6.29M | -6.56M | -8.04M | -8.99M | -7.53M | -8.63M | -10.06M | -9.67M | -8.73M | -8.68M | -1.55M | -17.42M | -11.35M | -14.47M | -14.10M | -6.96M | -7.67M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -408.99% | -250.40% | -326.32% | -367.14% | -193.93% | -224.12% |
| EPS | -0.03 | -0.04 | -0.06 | -0.07 | -0.07 | -0.09 | -0.11 | -0.11 | -0.11 | -0.12 | -0.02 | -0.26 | -0.17 | -0.24 | -0.27 | -0.16 | -0.22 |
| EPS Diluted | -0.03 | -0.04 | -0.06 | -0.07 | -0.07 | -0.09 | -0.11 | -0.11 | -0.11 | -0.12 | -0.02 | -0.26 | -0.17 | -0.24 | -0.27 | -0.16 | -0.22 |
| Weighted Avg Shares Out | 193.23M | 149.49M | 137.89M | 127.71M | 106.65M | 99.93M | 91.80M | 85.55M | 78.59M | 70.96M | 67.23M | 67.21M | 65.32M | 59.12M | 52.00M | 42.47M | 35.62M |
| Weighted Avg Shares Out (Dil) | 193.23M | 149.49M | 137.89M | 127.71M | 106.65M | 99.93M | 91.80M | 85.55M | 78.59M | 70.96M | 67.23M | 67.21M | 65.32M | 59.12M | 52.00M | 42.47M | 35.62M |
Helix BioPharma Corp. Announces Fiscal Third Quarter 2021 Results
Source: https://incomestatements.info
Category: Stock Reports